{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:06:02Z","timestamp":1789995962897,"version":"4.0.1"},"reference-count":14,"publisher":"American Chemical Society (ACS)","issue":"9","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, is widely used to treat ALK-positive nonsmall cell lung cancer. However, lorlatinib has occasionally been associated with severe liver injury. Immune-mediated adverse events are frequently provoked by certain pharmacological agents or their reactive metabolites. However, the specific contribution of immune pathways to hepatotoxicity caused by lorlatinib is yet to be fully elucidated. In the present study, the potential for direct inflammasome stimulation by lorlatinib was examined in differentiated THP-1 cells. This was accompanied by an evaluation of inflammasome-activating factors present in the culture supernatants of FLC-4 cells treated with lorlatinib. Our results showed that lorlatinib did not directly activate inflammasomes in differentiated THP-1 cells; however, the supernatants from FLC-4 cells activated inflammasomes in differentiated THP-1 cells following treatment with lorlatinib. Detection of pyrido-pyrazole-containing metabolites in FLC-4 cells suggests that these reactive metabolites activate inflammasomes. Exposure of FLC-4 cells to lorlatinib resulted in elevated extracellular concentrations of heat shock protein 90 (HSP90), a damage-associated molecular pattern (DAMP). These findings suggest that the reactive metabolites of lorlatinib promote hepatocellular release of damage-associated molecular patterns, which in turn activate inflammasomes. Thus, inflammasome activation may be an important step in the activation of the immune system by lorlatinib and may cause immune-related adverse events in some patients.<\/jats:p>","DOI":"10.1021\/acs.chemrestox.6c00327","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T16:03:32Z","timestamp":1786550612000},"page":"1878-1884","source":"Crossref","is-referenced-by-count":0,"title":["Investigation\nof the Mechanism of Lorlatinib-Induced\nHepatotoxicity: Reactive Metabolites of Lorlatinib Activate Inflammasomes"],"prefix":"10.1021","volume":"39","author":[{"given":"Takumi","family":"Noda","sequence":"first","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]},{"name":"National Hospital Organization Osaka National Hospital , ,","place":["Osaka, Japan, 540-0006"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Otsubo","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Takagaki","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Kidani","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Tamura-Takaori","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]},{"name":"Kansai Electric Power Hospital , ,","place":["Osaka, Japan, 553-0003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serina","family":"Mizuguchi","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]},{"name":"Osaka General Medical Center , ,","place":["Osaka, Japan, 558-8558"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Urashima","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]},{"name":"Japan Community Healthcare Organization Osaka Minato Central Hospital , ,","place":["Osaka, Japan, 552-0003"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Kohda","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7783-2599","authenticated-orcid":true,"given":"Ryuji","family":"Kato","sequence":"additional","affiliation":[{"name":"Osaka Medical and Pharmaceutical University , , ,","place":["Osaka, Japan, 569-1094"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"2026092108070996500_cit1","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib\nVersus Crizotinib in Patients With Advanced ALK-Positive\nNon\u2013Small Cell Lung Cancer: 5-Year Outcomes From the Phase\nIII CROWN Study","volume":"42","author":"Solomon","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"2026092108070996500_cit2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1021\/acs.chemrestox.6b00357","article-title":"How Reactive Metabolites Induce an Immune Response\nThat Sometimes Leads to an Idiosyncratic Drug Reaction","volume":"30","author":"Cho","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"2026092108070996500_cit3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1021\/acs.chemrestox.7b00065","article-title":"Supernatant from Hepatocyte\nCultures with Drugs That\nCause Idiosyncratic Liver Injury Activates Macrophage Inflammasomes","volume":"30","author":"Kato","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"2026092108070996500_cit4","doi-asserted-by":"publisher","first-page":"105606","DOI":"10.1016\/j.tiv.2023.105606","article-title":"Mechanism of non-steroidal\nanti-androgen-induced liver injury: Reactive\nmetabolites of flutamide and bicalutamide activate inflammasomes","volume":"90","author":"Kato","year":"2023","journal-title":"Toxicol. In Vitro"},{"key":"2026092108070996500_cit5","doi-asserted-by":"publisher","first-page":"120351","DOI":"10.1016\/j.lfs.2022.120351","article-title":"Role of caspase-8\nand\/or -9 as biomarkers that can\ndistinguish the potential to cause toxic- and immune related-adverse\nevent, for the progress of acetaminophen-induced liver injury","volume":"294","author":"Noda","year":"2022","journal-title":"Life Sci."},{"key":"2026092108070996500_cit6","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/jat.4585","article-title":"Reactive metabolite\nof trovafloxacin activates inflammasomes: implications\nfor trovafloxacin-induced liver injury","volume":"44","author":"Tanaka","year":"2024","journal-title":"J. Appl.\nToxicol."},{"key":"2026092108070996500_cit7","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1002\/jcph.1621","article-title":"Metabolism,\nexcretion, and pharmacokinetics\nof lorlatinib (PF-06463922) and evaluation of the impact of radiolabel\nposition and other factors on comparability of data across 2 ADME\nstudies","volume":"60","author":"Stypinski","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"2026092108070996500_cit8","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung\ncancer with ALK or ROS1 rearrangement: an international, multicentre,\nopen-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"2026092108070996500_cit9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.bbrc.2018.04.226","article-title":"ALK is required for\nNLRP3 inflammasome activation in\nmacrophages","volume":"501","author":"Zhang","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2026092108070996500_cit10","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1038\/s41467-021-23731-7","article-title":"Suppression of tumor-associated\nneutrophils by lorlatinib attenuates pancreatic cancer growth and\nimproves treatment with immune checkpoint blockade","volume":"12","author":"Nielsen","year":"2021","journal-title":"Nat. Commun."},{"key":"2026092108070996500_cit11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/ni1459","article-title":"A crucial function of SGT1 and HSP90\nin inflammasome\nactivity links mammalian and plant innate immune responses","volume":"8","author":"Mayor","year":"2007","journal-title":"Nat. Immunol."},{"key":"2026092108070996500_cit12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/00498254.2014.941964","article-title":"Metabolism, excretion and pharmacokinetics of [14C]\ncrizotinib following oral administration to healthy subjects","volume":"45","author":"Johnson","year":"2015","journal-title":"Xenobiotica"},{"key":"2026092108070996500_cit13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action,\nrole in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat. Med."},{"key":"2026092108070996500_cit14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrgastro.2015.200","article-title":"Immunology in the liver\nfrom homeostasis to disease","volume":"13","author":"Heymann","year":"2016","journal-title":"Nat. Rev. Gastroenterol.\nHepatol."}],"container-title":["Chemical Research in Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.chemrestox.6c00327","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/crtoec\/article-pdf\/39\/9\/1878\/66515528\/acs.chemrestox.6c00327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/crtoec\/article-pdf\/39\/9\/1878\/66515528\/acs.chemrestox.6c00327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:21:21Z","timestamp":1789993281000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/crtoec\/article\/39\/9\/1878\/5253656\/Investigation-of-the-Mechanism-of-Lorlatinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":14,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,8,12]]},"published-print":{"date-parts":[[2026,9,21]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.chemrestox.6c00327","relation":{},"ISSN":["0893-228X","1520-5010"],"issn-type":[{"value":"0893-228X","type":"print"},{"value":"1520-5010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}